Vir Biotechnology (VIR) Corporate presentation summary

Strategic vision and value drivers

• Near-term revenue sustainability targeted through commercialization of chronic hepatitis delta (CHD) therapy, with long-term growth from a robust cancer immunotherapy pipeline and strategic collaborations to maximize pipeline value.

• Discovery engine leverages world-class protein engineering, AI/ML optimization, and exclusive PRO-XTEN® masking technology, building on a legacy of infectious disease innovation.

• Financial position supported by $782M in cash and investments, with a projected cash runway into Q2 2028, bolstered by major collaborations such as with Astellas.

Chronic hepatitis delta (CHD) program

• CHD is a severe, underserved liver disease with high mortality and significant global prevalence; the combination therapy of tobevibart (mAb) and elebsiran (siRNA) targets both HDV and HBV with complementary mechanisms.

• Phase 2 SOLSTICE trial shows 88% of patients on monthly combo therapy achieved undetectable HDV RNA at week 96, with ~90% achieving low HBsAg levels by week 24 and maintaining suppression.

• ALT normalization rates were similar between combination and monotherapy, and the regimen demonstrated a favorable safety profile with mostly mild to moderate, transient adverse events.

• Registrational ECLIPSE Phase 3 program is fully enrolled and progressing ahead of schedule, with topline data expected in Q4 2026 and Q1 2027.

• Strategic partnership with Norgine provides exclusive commercial rights in Europe, Australia, and New Zealand, with significant upfront and milestone payments and royalties.

Oncology: masked T-cell engager (TCE) portfolio

• PRO-XTEN® masking platform enables TCEs to be activated only in the tumor microenvironment, reducing toxicity and expanding therapeutic potential in solid tumors.

• VIR-5500 (PSMA) for prostate cancer demonstrated favorable safety, no dose-limiting toxicities, and meaningful anti-tumor activity in heavily pretreated, late-line mCRPC patients, with 82% PSA50 response and 45% RECIST ORR at higher doses.

• Strategic collaboration with Astellas for VIR-5500 includes $1.7B in upfront and milestone payments, profit/loss sharing, and positions the asset for pivotal trials in 2027.

• Additional masked TCEs in clinical development include VIR-5818 (HER2) and VIR-5525 (EGFR), both showing promising early safety and efficacy data, with broad expansion into other solid tumors underway.

• Early data for VIR-5818 (HER2) show significant tumor shrinkage, high tolerability, and molecular responses in heavily pretreated patients, including those with traditionally resistant tumor types.